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1 Summary 
1 Summary 
The pancreatic β-cell hormone amylin decreases food intake via activation of brainstem neurons in the 
area postrema (AP). Diet-derived protein is thought to attenuate amylin responsiveness. Here we 
investigated the influence of isocaloric diets with differing protein contents on the amylin–dependent 
AP activation (c-Fos expression) and food intake suppression. Further, we investigated whether 
circulating amino acids affect these amylin actions. Finally, we characterized the possible interaction 
between amylin and glucagon, which is secreted in particular after a protein intake. 
 
1. The amylin-induced c-Fos expression is attenuated in rats fed an isocaloric diet with 18% 
protein content compared to rats fed with the 1% protein diet. Peripherally injected amino 
acids also attenuated the amylin-mediated AP activation.  
2. Amylin’s anorectic action was stronger in rats fed the 1% protein diet compared to its action 
in rats fed an isocaloric diet with higher protein content (8 and 18% protein).  
3. Glucagon did not induce a c-Fos response in the AP and it had no effect on the amylin-
dependent activation of AP neurons.  
 
This study extends the concept that diet-derived protein attenuates neuronal amylin responsiveness 
and amylin’s anorectic action, independently of caloric intake. Glucagon does not seem to be a 
mediator in this mechanism. Because the use of amylin analogs is a promising approach for the 
treatment of obesity the current findings might be therapeutically relevant. 
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2 Zusammenfassung 
2 Zusammenfassung  
Das Pankreashormon Amylin hemmt die Nahrungsaufnahme über die Aktivierung von Neuronen in 
der Area postrema im Hirnstamm. Nahrungsproteine scheinen die Amylinsensitivität abzuschwächen. 
Wir untersuchten den Einfluss von isokalorischen Diäten mit unterschiedlichem Proteingehalt auf die 
Amylin - vermittelte AP-Aktivierung (c-Fos Expression) und die anorektische Wirkung von Amylin. 
Ebenfalls wurde untersucht, ob zirkulierende Aminosäuren diese Amylinwirkungen beeinflussen und 
ob es eine mögliche Interaktion zwischen Amylin und Glukagon gibt, welches v.a. nach 
Proteinaufnahme sezerniert wird. 
 
1. Die Amylin induzierte c-Fos Expression war bei der 18% Protein Diät schwächer als nach 
Gabe der 1% Protein Diät. Peripher injizierte Aminosäuren schwächten die Amylin vermittelte 
c-Fos Expression ebenfalls ab. 
2. Amylin's anorektische Wirkung war stärker bei der 1% als bei der 8% oder der 18% 
Proteindiät. 
3. Glukagon induzierte keine c-Fos Expression in der AP und hatte auch keinen Einfluss auf die 
von Amylin abhängige Aktivierung der AP Neurone.  
 
Die vorliegende Studie sichert die Hypothese, dass Protein die neuronale Amylinresponsivität und die 
anorektische Wirkung von Amylin abschwächt. Dieser Effekt hängt nicht von der Kalorienaufnahme 
ab. Glukagon scheint keinen Einfluss auf diesen Mechanismus zu haben. Da Amylin-Analoga einen 
vielversprechenden Ansatz zur Bekämpfung der Fettleibigkeit darstellen, sind die vorliegenden 
Ergebnisse eventuell auch therapeutisch relevant. 
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3 Introduction 
3 Introduction  
The long term balance of energy intake and energy expenditure is a fundamental requirement for a 
normal body function. Food intake provides macronutrients that are used as metabolic fuels and to 
maintain normal cellular structure and function (Woods et al., 2000). Various control signals that 
reflect the body’s energy status act at different target sites in the body to maintain energy homeostasis. 
Generally, the multitude of signals is categorized into satiation and adiposity signals. Endogenous 
factors that physiologically control the size of an ongoing meal are considered satiation signals 
(Woods et al., 2004). Cholecystokinin (CCK) is the best investigated hormonal satiation signal in this 
regard. CCK is released from the duodenum in response to food intake. Further, the pancreas produces 
the two anorectic peptide hormones amylin and glucagon that both reduce meal size when 
administered systemically (Geary and Smith, 1982; Weatherford and Ritter, 1988; Morley and Flood 
1991; Lutz et al., 1994; Lutz et al. 1995). There are two major ways how these peptides signal to the 
central nervous system (CNS). These signals involved in the control of energy balance may reach the 
brain via the neural pathway or by direct humoral action on the brain. CCK and glucagon, for 
example, act via afferent vagus nerve fibers, which transmit the excitatory input to the hindbrain. 
Amylin and some metabolic factors act via the humoral pathway.  
The two best investigated hormones that are considered adiposity signals are leptin, which is secreted 
from white adipose cells and insulin which is secreted from pancreatic β - cells (Woods et al., 2004). 
Adiposity signals fulfill the following criteria. They circulate at levels proportional to body fat and 
enter the CNS in proportion to their plasma level. Administration of either peptide directly into the 
brain reduces food intake, whereas deficiency of either hormone leads to an opposite effect (Schwartz 
et al., 2000). Leptin and insulin are believed to act primarily on neurons located in the hypothalamic 
arcuate nucleus where they interact with neurons that synthesize the proopiomelanocortin (POMC) 
derived anorectic neuropetide alpha-MSH or the orexigenic neuropeptide Y (NPY), repectively. 
 
3.1 The area postrema / nucleus tractus solitarii region and its projections  
The area postrema (AP), which is located on the dorsal surface of the medulla oblongata at the caudal 
end of the brain stem, belongs to the circumventricular organs (CVO) that are specialized areas of the 
brain with fenestrated capillaries. The CVO are subdivided into sensory and neurosecretory structures. 
The first group comprises the AP, the subfornical organ (SFO) and the organum vasculosum laminae 
terminalis. The eminentia mediana, the pineal organ and the posterior pituitary, or neurohypophysis, 
are classified as neurosecretory CVO (Fry and Ferguson, 2007).  
All CVO lack a functional blood-brain barrier (BBB). The BBB typically isolates the CNS from the 
rest of the body and protects the CNS from changes in the peripheral electrolyte concentrations, from 
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toxins and also from pathogens. The BBB also prevents brain intrinsic neuropeptides, transmitters and 
growth factors from diffusing out of the CNS into the general circulation (Fry and Ferguson, 2007).  
One of the first recognized roles of the AP was its function as the chemoreceptor trigger zone, which 
is involved in the induction of nausea and emesis as protective mechanisms against intoxications 
(Harding et al., 1985; Miller and Leslie, 1994). More importantly for the work presented here, the AP 
is an important target area for circulating hormones. In particular, it is the primary target site for 
amylin, which directly activates AP neurons (Rowland et al., 1997; Riediger et al., 2004) (see below).  
The nucleus of the solitary tract (NTS), which is located in close proximity to the AP, is reciprocally 
connected to the AP via monosynaptic projections (Ferguson, 1991). Therefore, it is a site of 
convergence for satiation signals acting via the vagus nerve (e.g. CCK) and via the AP (e.g. amylin). 
Further connections from the NTS project to the lateral parabrachial nucleus (lPB), the central nucleus 
of the amygdala (Ce) and the lateral subdivisions of the bed nucleus of the stria terminalis (BSTL) 
(Riediger et al., 2004). These brain structures (AP, NTS, lPB, Ce, BSTL) are part of the central 
gustatory/enteroceptive system and are mutually interconnected and linked to the hypothalamus, the 
main integrative centre for the control of energy balance (Saper et al., 2002).  
 
3.2 Amylin 
The molecular structure of amylin was discovered in 1987 (Cooper et al., 1987; Westermark et al., 
1987). Amylin is a 37 amino acid peptide hormone which is co-secreted with insulin from pancreatic 
β-cells at a molar ratio of approximately 100:1 (insulin : amylin) in response to food intake (Butler et 
al., 1990; Kahn et al., 1990; Ludvik et al., 1997).  
Amylin is a member of the calcitonin peptide family, together with calcitonin, α and β calcitonin - 
gene related peptide (CGRP) and adrenomodullin (AM) (Wimalawansa, 1997). Amylin binds to the 
calcitonin core receptor (CTR) with ligand specificity being conferred by receptor activity modifying 
proteins (RAMP’s) that heterodimerize with the CTR receptor (Chen et al., 1997; Christopoulos et al., 
1999).  
Functional amylin receptors are named AMY 1(a), AMY 2(a), AMY 3(a); (a) stands for the heterodimer of 
the type a calcitonin receptor (CTa), the numbers 1, 2, 3 indicate the association with RAMP 1, RAMP 
2 or RAMP 3 (Poyner et al., 2002). 
Autoradiographic studies by (Sexton et al., 1994) demonstrated that amylin binding occurs with high 
density in the sensory CVO’s and the ventromedial hypothalamic nucleus. Becskei (Becskei et al., 
2004) investigated the distribution of the CTR gene in adult rat brains by immunohistochemical 
methods. She found an abundant expression of CTR in many areas of the brain, with high densities in 
the AP/NTS region.  
One of amylin’s best-investigated functions is its inhibitory effect on food intake which is mediated by 
the AP (Morley and Flood, 1991; Lutz et al., 1994). At physiological plasma levels, amylin also 
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inhibits glucagon secretion (Fehmann et al., 1990; Young, 2005a) and reduces the rate of gastric 
emptying (Young, 2005 b). Similar to amylin’s anorectic action, these effects are also thought to be 
mediated by the AP.  
Amylin activates AP neurons after peripheral administration (Rowland et al., 1997; Michel et al., 
2007); most of these studies made use of the immunohistological detection of the immediate early 
gene product c-Fos as a marker of neuronal activation (Hoffman et al., 1993; Hughes and Dragunow, 
1995). Interestingly, endogenously released amylin also seems to activate the AP because a refeeding 
induced c-Fos expression in 24h fasted rats has been shown to be attenuated in rats pre-treated with a 
specific amylin receptor antagonist (Riediger et al., 2004). In line with this observation, intravenous 
infusion of an amylin receptor antagonist leads to an increase in food intake suggesting that 
endogenous amylin physiologically inhibits feeding (Mollet et al., 2004). At the cellular level it has 
been demonstrated that amylin leads to an excitation of AP neurons, which seems to be mediated by 
an intracellular formation of the second messenger cGMP (Riediger et al., 2001). 
 
3.3 Therapeutic approaches using amylin agonists 
Obesity is a major health problem in humans and animals worldwide and is considered as an epidemic 
by the World Health Organization (WHO, 2009). The prevalence of obesity is rising and promotes the 
development of severe secondary health problems like cardiovascular disease, type II diabetes, sleep 
apnea, musculoskeletal disorders and some cancers, as well as many psychosocial disorders (Aronne 
et al., 2009). Based on the finding that amylin and insulin are normally cosecreted from pancreatic β 
cells, amylin replacement is used as an adjunct therapy with insulin in type I and type II diabetes 
therapy. Due to its ability to lower the rate of gastric emptying and to inhibit postprandial glucagon 
secretion (Young, 2005a), amylin slows down the flux of carbohydrates into the circulation (Young 
and Denaro, 1998) and hence contributes to an improved control of postprandial glycemia compared 
to insulin alone. The amylin agonist pramlintide is approved in the USA as a therapeutic drug for the 
treatment of human type II diabetes.  
Apart from surgical approaches (e.g. Roux-en-Y gastric bypass surgery or gastric banding (Benotti et 
al., 1989; Peterli et al., 2009)), the development of therapeutic strategies for the treatment of obesity 
has not been very successful in the past. Several pharmacological approaches were either not effective 
or were associated with major undesired side effects so that several drugs have recently been 
withdrawn from the market. However, new promising hormonal treatment strategies emerged recently 
that are based on combined administration of amylin and leptin agonists. Preclinical rodent studies and 
clinical trials with humans have shown that a combination therapy of amylin and leptin is more potent 
than the weight-lowering effect of amylin or leptin alone (Roth et al., 2007; Roth et al., 2008; 
Ravussin et al., 2009). These findings not only indicate that amylinergic drugs are important 
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therapeutic targets for the treatment of obesity and associated metabolic disorders, but they also imply 
that the clinical efficacy of amylin is modulated by other factors. 
 
3.4 Aim and hypothesis 
The potency of some anorectic hormones depends on the macronutrient composition of the diet. For 
example, centrally administered glucagon-like peptide 1 (GLP-1) reduced food intake when given 
concurrently with a meal or a preload of carbohydrate but not when a protein preload was given (Choi 
and Anderson, 2001). Similarly, the effect of CCK seems to be nutrient-dependent because CCK 
inhibited and the CCKA receptor antagonist L-364,718 enhanced carbohydrate intake, but not protein 
intake when offered as an intra-oral amino acid infusion (Mamoun et al., 1997). Most studies 
investigating the anorectic effect of amylin after acute treatment used standard rodent chow (Rushing 
et al., 2001) or a medium fat diet (Lutz et al., 1998a; Lutz et al., 1998b) without directly comparing 
amylin’s feeding inhibitory action under different diet conditions. It has been demonstrated, however, 
that under chronic amylin treatment rats not only decreased their energy intake, but that they also 
shifted their intake preference from a high-fat diet to low-fat dietary components (Mack et al., 2007). 
In a recent study conducted by our group (Michel et al., 2007) amylin’s potency to reduce food intake 
and to induce c-Fos expression in the AP/NTS region was affected by the macronutrient content of the 
diet. A low dose of peripheral amylin (5µg/kg) induced a strong c-Fos expression in the AP/NTS in 24 
hrs fasted rats, but not in rats that were fed ad libitum. The same dose also induced a strong c-Fos 
response in rats that received a nutrient deficient diet called non caloric mash (NCM) for 24 hrs before 
injection. As determined by selective nutrient supplementation to NCM, protein seemed to attenuate 
both the amylin-induced activation of the AP/NTS region and the inhibitory effect on feeding. The 
same was not observed with glucose or fat added to NCM. Interestingly, the protein dependent 
attenuation of amylin’s anorectic effect did not occur in chow-fed rats although the intake of protein 
was similar in these animals when compared to the protein intake of rats fed the protein supplemented 
non-caloric diet. These findings put forward the hypothesis that the inhibitory effect of protein on 
amylin’s anorectic effect and possibly on other AP-mediated functions might be modulated by the 
presence of other macronutrients (carbohydrates and fat) in the diet. In other words, when isocaloric 
diets are offered, the ability of amylin to reduce food intake and to activate the AP might increase with 
decreasing protein content of the diet.  
Therefore it was one aim of the present study to investigate the influence of proteins and of an amino 
acid mixture on amylin induced c-Fos expression and amylin's anorectic action in more detail. We 
tested the influence of three isocaloric diets which differed only in their protein content (18%, 8%, 
1%), on the amylin induced activation of the AP and on amylin’s effect to reduce food intake. 
Furthermore we sought to determine whether an acute rise in plasma amino acids following an 
intraperitoneal injection of an amino acid mixture is sufficient to attenuate amylins neuronal 
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responsiveness. A negative outcome of the latter study would suggest that a direct effect of circulating 
diet-derived amino acids is not important for the protein-dependent attenuation of amylin-
responsiveness.  
Because glucagon plasma levels are particularly elevated during the course of protein meals in rats and 
humans (Geary et al., 1981), and because amino acids (especially arginine, alanine and glutamine) are 
potent stimulators of glucagon secretion (Pipeleers et al., 1985; Young and Denaro, 1998; Dumonteil 
et al., 2000) we assumed that glucagon might play a role in the modulation of amylin induced c-Fos 
expression in the AP/NTS region. 
 
Summary of specific questions: 
Do isocaloric diets that differ in their protein content influence amylin’s anorectic effect and the 
amylin - induced c-Fos expression in the AP/NTS?  
Do peripherally administered amino acids influence amylin’s anorectic effect and the amylin - induced 
activation (c-Fos expression) in the AP? 
Does glucagon modulate the amylin - induced c-Fos expression in the AP/NTS region? 
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4.1 Animals and housing 
Male Wistar rats (Elevage Janvier, Le - Genest - St - Isle, France) were used in all experiments; their 
mean body weight was about 300 g at the start of the experiments. The rats were adapted to the 
housing conditions and to handling (taking them out of the cage, weighing, performing injections) for 
at least seven to ten days before the experiments started. 
The animals had ad libitum access to tap water and to standard laboratory rodent chow (3430; Provimi 
Kliba, Gossau, Switzerland Table 1), except during periods when the animals received specific test 
diets or during food deprivation as described below. All rats were individually housed in hanging, 
stainless steel wire cages (50 x 25 x 18 cm) under controlled conditions of illumination (12:12 h light 
– dark cycle), humidity and temperature (21 ± 1°C). The Veterinary Office of the Kanton Zurich, 
Switzerland, approved all animal procedures and experiments.  
 
4.2 Diets 
In addition to standard chow, different test diets were used. 
We used three isocaloric diets (Provimi Kliba AG; Kaiseraugst, Switzerland), which differed in their 
protein content (18%, 8%, 1%; Table 1) and a diet called non-caloric mash (NCM) (Michel et al., 
2007) for the feeding and c-Fos studies. NCM is composed of 2.5 parts by weight α-cellulose, 1.0 part 
mineral oil, 10.0 parts deionised water solution containing 0.1% sodium saccharin, and 0.2% vanilla 
extract (Altromin, Lage, Germany). The NCM diet was freshly prepared before each experiment. Prior 
to each experiment, the animals were adapted to the new diets in the habituation period. During this 
period, the diets were offered two times for 24 hrs, together with standard chow; during one additional 
day immediately before the test phase, the diet was offered alone.  
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Table 1 Compositions of standard laboratory chow and the three isocaloric diets of different protein 
content used in the c-Fos and feeding studies (NfE = nitrogen free extract). Distributed by Provimi 
Kliba AG, Kaiseraugst, Switzerland. 
   chow 18% protein 8% protein 1% protein 
in % (w/w)      
dry matter  88 90 90 90 
 protein 18.5 18 8 0.7 
 fat 4.5 4.5 4.5 4.5 
 ash 6.3 3.0 3.1 3.1 
 starch 35 38 48 58 
 NFE 54.2 61 70.90 78.15 
 simple sugars (sucrose, dextrose) 19.2 23 22.9 20.15 
 fiber 4.5 3.5 3.5 3.5 
energy ME (MJ/kg) 13.2 15.4 15.2 15.1 
 
4.3 Technical procedures 
4.3.1 Immunohistochemistry (c-Fos studies) 
To investigate c-Fos expression in the AP/NTS region, weight-matched animals were either food-
deprived or fed with the 1% and 18% protein diets respectively. The animals were maintained under 
these conditions for 24 hours starting from the beginning of the dark phase one day before injections. 
At the onset of the following dark phase, the rats received a s.c. injection (1ml/kg) of rat amylin 
(5µg/kg; Bachem, Bubendorf, Switzerland) or NaCl (NaCl 0.9% B. Braun, B. Braun Medical AG, 
Sempach, Switzerland) for control. Amylin was dissolved in 0.9% NaCl.  
 
Two hours after the respective treatments, the animals were deeply anaesthetized with pentobarbital 
sodium (100 mg/kg i.p.; Pentobarbital sodium, 50 mg/ml; Kantonsapotheke Zürich, Switzerland); the 
absence of reflexes (tail and toe reflex) was tested. Then, i.e. after reaching surgical tolerance, the 
abdomen was opened and the diaphragm was cut. After cutting the costal arches laterally on both 
sides, the thorax was opened. The left ventricle of the heart was penetrated with a cannula (Terumo 
18G x 1/2, Leuven, Belgium) and ice-cold phosphate buffer solution (PB 0.1 M, pH 7.2) was infused 
for 1.5 min; the right atrium was opened before the heart was incised with a pair of scissors. The 
perfusion of PB was followed by ice-cold 4% paraformaldehyde solution (4% PB 0.1 M) for in situ 
fixation of the tissue for 2 min.  
The brains were removed and post fixed for additional two hours in a 4% paraformaldehyde solution 
(4% PB 0.1 M) at 4 °C. After incubation for 48 hours in 20 % sucrose in PB for cryoprotection, the 
brains were transsected between the cerebrum and the cerebellum. Both parts of the brain were put on 
parafilm strips partly covered with tissue freezing medium and snap frozen with CO2 for 
approximately 1 min.  
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Two series of 20 µm coronal sections of the medulla oblongata at the level of the AP/NTS (Paxinos et 
al., 2007) were cut in a cryostat (Leica CM 3050 S, Nussloch, Germany), thaw mounted on adhesive 
glass slides (Super Frost Plus; Menzel Braunschweig, Germany) and stored at -20°C. 
 
After air drying for one hour at room temperature the slides were rehydrated in phosphate buffered 
saline (pH 7.4) containing 0.1% Triton X – 100 (PBST) for half an hour. The sections were incubated 
either in normal goat serum or in normal rabbit serum (1.5% in 0.3% PBST) for two hours to prevent 
unspecific binding.  
Two different primary antibodies were used for the detection of c-Fos expression. Initially, 
immunohistological detection of c-Fos expression was performed using a goat polyclonal anti-c-Fos 
antibody IgG (Santa Cruz Biotechnology, Heidelberg, Germany) in 0.3% PBST (1:10.000) for 48 hrs 
at 4 °C. However, due to a high non-specific background staining with this antibody, a second primary 
antibody (rabbit polyclonal anti-c-Fos (Ab-5) (4-17) (Calbiochem, Darmstadt, Germany) in 0.3% 
PBST (1:5.000) was employed in later experiments. 
After washing in 0.1% PBST (5 x 10 min), the brain sections were incubated with the secondary 
antibody (in 1:1.000 biotinylated rabbit anti goat antibody, Vectastain Elite ABC Kit; Vector 
Laboratories, Burlingame, California USA or in 1:400, biotinylated goat anti rabbit, Vector 
Laboratories) for 90 minutes at room temperature. After 1h incubation in avidin-biotin complex 
(Vectastain Elite ABC Kit), c-Fos was visualized by incubation in biaminobenzidine solution (0.04% 
buffered saline with 0.02% H2O2, 0.08% NiCl, and 0.01% CoCl; Sigma Aldrich) for five to seven 
minutes. The slides were rinsed in PBST, dehydrated in graded alcohol, immersed in xylol, and cover 
slipped with Entellan (Merck, Darmstadt, Germany). All incubations were done on Plexiglas plates 
(Max Planck Institut, Bad Nauheim, Germany) in closed and wet metal boxes.  
 
C-Fos stainings were evaluated using a microscope equipped with a digital camera (Axioskop; Carl 
Zeiss, Feldbach, Switzerland). The experimenter was blinded to the experimental groups. C-Fos 
positive cells were counted in every fourth section of the AP/NTS region, resulting in approximately 
six sections per animal (AP/NTS – bregma -14.30 mm to - 13.56 mm). The cell counts were averaged 
for each animal. Group mean values ± SEM were calculated from the averaged cell counts of each 
animal for each treatment group (n = number of animals). 
 
4.3.2 Blood sampling 
Blood samples were taken from each rat by cardiac puncture just before perfusion or from the lingual 
vein under isoflurane anaesthesia. Immediately after blood collection, the concentration of glucose 
was measured using a glucose-oxidase based glucometer (Glucometer Elite; Bayer, Zürich). The blood 
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was transferred into serum tubes (Microvette 500 Z, Sarstedt, Germany) and centrifuged at 2800 rpm 
for ten minutes. The serum was then removed and frozen at -20 °C.  
When hormone blood levels were measured with a LINCOplex Kit (Rat endocrine kit for measuring: 
insulin, glucagon, amylin, leptin; rat gut kit for measuring: peptide tyrosine tyrosine, pancreatic 
polypeptide; Millipore Corporation, Billerica, MA, USA); a protease inhibitor cocktail (P 2714, Sigma 
- Aldrich) was immediately added after blood sampling (10 µl of the inhibitor / 1 ml blood).  
 
4.3.3 Immunoassay for plasma hormone levels (LINCOplex KIT) 
The rat endocrine (Cat. No.: RENDO - 85K) and the rat gut (Cat. No.: RGT – 88K) LINCOplex 
assays (Millipore corporation, Billerica, MA, USA) were used for the analysis of serum samples. The 
LINCOplex assay is a multianalyte detection system and was used according to the manufacturer’s 
instructions. Briefly, the assay is based on conventional sandwich assay technology and permits 
simultaneous detection of multiple hormones from a single sample. The antibody specific for the 
hormone of interest is covalently coupled to Luminex micro spheres uniquely labelled with fluorescent 
dye. 
The microspheres were incubated overnight (17 hrs) at 2-8°C with standards, controls and the serum 
samples (10 µl of the sample for the endocrine kit and 25µl of the sample for the gut hormone kit) in a 
96-well microtiter filter plate with agitation on a plate shaker. 
After incubation, the plate was washed three times with an assay wash buffer (200 µl/well) to remove 
excess reagents between each washing step and prior to the addition of the detection antibody (50 
µl/well). After sixty minutes of incubation on a plate shaker at room temperature, 50 µl streptavidin – 
phycoerythrin were added to each well containing 50 µl of detection antibody cocktail, and incubated 
for thirty minutes.  
After a final washing step (washing and removing fluids by vacuum filtration 3 times), the beads were 
resuspended in buffer (100 µl sheath fluid) and the plate was analyzed using the Luminex 100 
analyzer to determine the concentration of the hormones of interest.  
 
4.3.4 Amino acid measurements 
The measurements of amino acid concentrations were performed by the Functional Genomics Centre 
(FGCZ) at the University of Zurich in Switzerland. 80µl of each serum sample were used and 80µl of 
a 10% sulfasalicyclic acid solution (SSA) was added for precipitation. 20µl of the supernatant was 
taken and 60µl borate buffer were added to the vial and reconstituted with 20µl MassTrak Amino Acid 
Analysis Solution derivatization reagent. 1µl of this vial was injected into the Waters Acquity Ultra 
Performance Liquid Chromatography (UPLC) machine equipped with an UV detector (Waters 
Corporation, Milford, MA, USA) and the samples were analyzed. Analyses were carried out according 
to the manufacturer's instructions. 
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4.4 Experimental design 
4.4.1 Effect of isocaloric diets with different protein contents on the anorectic 
effect of amylin and on the amylin-induced c-Fos expression in the AP/NTS 
Blood sampling for measurements of amino acid baseline levels and plasma hormone levels at the 
onset of the dark phase  
 
First the animals were adapted to the new diets, which were offered twice during two dark phases in a 
habituation period of seven to ten days. Then the animals received chow for another 48 hrs. After this 
period, the animals received chow and the test diet for 24 hrs and were then fed the special diets only 
for 48 hrs beginning at dark onset; blood sampling was conducted at dark onset the other day to 
measure the baseline amino acid levels (tongue blood).  
For the measurement of plasma hormone levels after an amylin injection, rats were treated as 
described above. At dark onset, they received an injection of 5µg/kg amylin s.c. and 20 min later 
blood was collected from the tongue vein. 
 
Effect of the three isocaloric diets that differ in their protein content on amylin’s anorectic effect  
 
The anorectic effect of amylin was tested in a crossover design. The animals were adapted for seven to 
ten days to the experimental conditions. During this time the animals received the isocaloric diets that 
differed in protein content on two days for 24 hrs beginning always at the beginning of dark onset. 
After this habituation period, the animals were allocated to two weight-matched groups and a period 
of another 48 hrs of chow feeding followed. Then the animals received another 24 hrs chow and the 
test diet. At the day of testing, all animals had been exposed to the test diet for 24 hrs and diet groups 
were then subdivided into one amylin-treated (5µg/kg s.c.) group and one control group receiving 
saline (n = 7 for all groups). Injections were at dark onset. The cumulative food intake was measured 
30 min, one hour and two hours after injection with a precision of 0.1g and correction for spillage. The 
animals were kept on the diet until 24 hrs after the injection and then switched back to chow. After a 
two-day period of chow feeding the rats were fed according to the same feeding regimen; but at the 
next trial at onset of the dark phase, the treatment groups were exchanged and tested using a crossover 
design. After another period of two days of chow feeding, this paradigm was repeated to test the 
effects of the next diet (order diets: trial 1 1% protein diet, trial 2 18% protein diet, trial 3 8% protein 
diet (Figure 1) ).  
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Figure 1 Example of how a feeding study was conducted 
 
Interaction of an 18% and 1% protein diet with amylin and the effect on c-Fos expression in the AP 
 
In this experiment we tested whether rats showed a difference in the amylin-induced c-Fos expression 
in the AP, depending on the protein content of the diet (Table 1). The animals received either the 1% 
or the 18 % protein diet for 48 hrs according to the regime used in the feeding study. Each of these 
diet groups was then subdivided into one amylin-treated (5µg/kg s.c.) group and one control group 
receiving saline (n = 7 for all groups) at dark onset. Rats were allowed to continue feeding for 2 hours 
until sacrifice (perfusion).  
 
4.4.2 Effect of peripherally administered amino acids on the anorectic effect of 
amylin and on the amylin-induced c-Fos expression in the AP 
 
Blood amino acid levels after injection of two different doses of amino acid  
 
We first performed a pilot experiment to investigate the time course of blood amino acid levels after 
the injection the of two different doses of the amino acid mixture. We used a commercial amino acid 
solution Aminoven 15% (Fresenius Kabi Schweiz AG) which contains 16 different amino acids. This 
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solution is used in human medicine for parenteral nutrition. It contains eight essential, two semi-
essential and six non-essential amino acids (for further information see Table 2). 
The animals were food-deprived for 24 hrs and divided into three groups, including a control group (n 
= 4) that did not receive Aminoven, and two groups injected with 1g/kg or 2g/kg Aminoven (n = 8 for 
both groups). 
Aminoven 15% solution was injected intraperitoneally with sterile syringes (Omnifix, Braun 
Melsungen AG, Melsungen, Germany) and sterile needles (Terumo, 26G, Leuven, Belgium). 
 
Blood was sampled just before (0 min) and 20 min and 60 min after injection. At each time point, 
different animals were used. The animals were anaesthetized with isoflurane and blood was taken by 
cardiac puncture. Amino acid, blood glucose and hormone levels (insulin, amylin, leptin, glucagon, 
PP, PYY) were determined.  
 
Table 2 Content of amino acids in Aminoven 15% (150g total amino acids/litre solution) distributed 
by Fresenius Kabi Schweiz AG 
Aminoven 15%    
 g/mol g/l mol/l 
    
l-isoleucine 131.17 5.2 0.039643211
l-leucine 131.18 8.9 0.067845708
l-lysine 146.19 11.1 0.075928586
l-methionine 149.21 3.8 0.025467462
l-phenylalanine 165.19 5.5 0.033294994
l-threonine 119.12 8.6 0.072196105
l-tryptophane 204 2 0.007834381
l-valine 117.15 5.5 0.046948357
arginine 174.2 20 0.114810563
l-histidine 155.16 7.3 0.047048208
alanine 89.09 25 0.280615108
glycine 75.07 18.5 0.246436659
l-proline 115.13 17 0.147659168
l-serine 105.09 9.6 0.091350271
l-tyrosine 181.19 0.4 0.002207627
taurine 125.14 2 0.0159821 
total 2183.508 150 1.315268509
 
Effect of Aminoven on amylin’s anorectic effect  
 
To test the effect of prior Aminoven injection (20 min before dark onset) on amylin’s anorectic effect, 
we conducted a feeding study with 24 animals divided into four weight-matched groups. The groups 
had been adapted to their diets for seven to ten days. During this time the animals received the 1% 
protein diet twice. 48 hrs before the feeding trials, the animals received again the 1% protein diet; 
then, they received the respective Aminoven, amylin or control treatments. Cumulative food intake 
 14
4 Animals, Material and Methods 
was measured 30 min, 1 hr and 2 hrs after injections with a precision of 0.1g and correction for 
spillage. After a 2-3 day period of chow feeding, the rats were fed the same diet again for 48 hrs; at the 
onset of the dark phase, the treatment groups were exchanged and tested in a crossover design.  
 
Effect of Aminoven on amylin-induced c-Fos expression in the AP  
 
To test the effect of an Aminoven injection on amylin-induced c-Fos expression in the AP, four 
weight-matched groups including a saline control group (n=5), an amylin-treated group (n=7), an 
Aminoven control group (n=8) and a group that was treated with Aminoven and amylin (n=7) were 
used. The Aminoven dose was chosen according to the results of the blood amino acid level 
measurements after injection of two different amino acids. The 1g/kg dose was chosen because it 
induced a rise of amino acid levels without affecting blood glucose levels.  
The animals were food-deprived for 24 hrs and injected with Aminoven (1g/kg i.p.) or saline 20 min 
before dark onset. At dark onset, amylin (5 µg/kg s.c.) or saline were injected. Two hours after these 
treatments, the animals were deeply anaesthetized and transcardially perfused. Blood was sampled and 
the glucose concentration was measured as described.  
 
4.4.3 Effect of glucagon on the amylin-induced c-Fos expression in the AP 
In this experiment, we investigated if an acute injection of glucagon (Gluca Gen® Novo Nordisk, 1mg 
Küsnacht, Zürich; Switzerland Charge No. XW60072) influences the amylin induced c-Fos expression 
in the AP. In accordance with previous studies (Geary and Smith, 1982; Langhans et al., 1986; Lutz et 
al., 1996), we chose glucagon doses of 100µg/kg i.p. or 500µg/kg i.p. for the injections. The animals 
were food deprived for 24 hrs and allocated into six groups ( saline / saline; saline / amylin; glucagon 
100µg/kg / saline; glucagon 100µg/kg / amylin; glucagon 500µg/kg / saline; glucagon 500µg/kg / 
amylin). The rats received glucagon or NaCl 0.9% 10 min before dark onset. At dark onset, rats 
received either 5µg/kg of amylin or NaCl 0.9% injection as control; two hours later, the animals were 
perfused.  
4.5 Statistical Analysis 
All results are presented as mean values ± SEM. Differences in food intake were analyzed using a 
paired Student’s t-test to compare the differences between amylin-treated and their control groups at 
each time point. Differences in amino acid or hormone levels between the treatment groups were 
analyzed using an unpaired t-test. For all other studies, the results were compared separately for each 
experiment using one way ANOVA or one way ANOVA on ranks for data that were not normally 
distributed, followed by the Student-Newman-Keuls post hoc test. In the immunohistological studies, 
the mean value of the cell counts/section of an individual animal was used for statistical analyses. In 
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all cases p < 0.05 was considered significant. Data were statistically analyzed using the software Prism 
Version 5. 
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5.1 Effect of isocaloric diets with different protein contents on the 
anorectic effect of amylin and on the amylin-induced c-Fos expression 
in the AP/NTS 
 
Blood amino acid levels for different test diets 
 
The first experiment tested the effect of 48 hrs intake of diets with differing protein content on the 
concentration of amino acids in the blood. At the onset of the dark phase, blood samples were taken 
from the tongue vein. We observed a significant difference in the total blood concentration of amino 
acids among the three isocaloric diets that differed in their protein content (mean values: 1% protein 
diet 3102 ± 257.3 µmol/l (n=4); 8% protein diet 3969 ± 83.2 µmol/l (n=6); 18% protein diet 5562 ± 
534.2 µmol/l (n=5); standard laboratory chow (approximately 18.5 % protein) 5306 ± 343.7 µmol/l 
(n=4)). Hence, chow fed rats had similar blood amino acid concentrations than rats fed the 18% 
protein diet. For illustration see Figure 2. Importantly, the blood glucose concentration did not differ 
significantly among rats receiving the three isocaloric diets different in protein content (Figure 3). 
 
 
Figure 2 Blood level of total amino acids measured in animals receiving the different test diets for 48 
hrs; chow (dotted line) has a similar protein content as the 18% protein diet and resulted in similar 
blood amino acid levels. Data are expressed as means ± SEM. Different letters indicate significant 
differences (p < 0.05; one way ANOVA) (n: 1% = 4 ; 8% = 6; 18% = 5; standard laboratory chow 
=4) . 
 17
5 Results 
  
 
Figure 3 Average blood glucose concentration measured in animals receiving the respective diets (see 
Figure 2)  for 48 hrs. Data are expressed as means ± SEM. Bars with different letters are significantly 
different (p < 0.05; one way ANOVA) (n: 1% = 4 ; 8% = 6; 18% = 5) 
 
Plasma amylin levels after amylin injection in rats fed the different test diets  
 
The increase in plasma amylin levels produced by the amylin injection in rats fed with the different 
protein diets for 48 hrs was significant in all amylin treated animals (1% protein diet: saline injected 
6.9 ± 3.4 pM (n=3), amylin injected 161.5 ± 36.9 pM (n=6); 8% protein diet: saline injected 10.8 ± 3.5 
pM (n=6), amylin injected 121.0 ± 23.9 pM (n=6); 18% protein diet: saline injected 8.3 ± 1.2 (n=4), 
amylin injected 133.7± 30.8 (n=6)). There were no significant differences among groups in saline or 
amylin treated rats, respectively. See Figure 4. 
 
Figure 4 Blood amylin levels after an amylin injection of 5ug/kg s.c. in rats fed the different test diets 
for 48 hours. Amylin was measured 20 min after injection.  
 18
5 Results 
 
Effect of the three isocaloric diets different in their protein content on amylin’s anorectic effect  
 
Baseline food intake of rats eating the three isocaloric diets that differed in protein content was 
measured over 48 hrs. Data showed that rats ate the same amount of food of the 1% protein diet and of 
the 18% protein diet, but that rats receiving the 8% protein diet ate significantly less than rats on the 
other diets (mean food intake values: 1% protein diet 9.9 ± 0.6 g; 8% protein diet 7.6 ± 0.1 g; 18% 
protein diet 9.2 ± 0.3 g). See Figure 5.  
Amylin significantly reduced food intake across all groups , i.e. in rats fed the 1%, the 8% or the 18% 
diet. The amylin-induced reduction in food intake was significant after 30 min and 60 min under all 
three conditions (Figure 6). After 120 min, amylin only reduced intake in the rats fed the 1% protein 
diet, but not when the 8% or the 18% protein diets were offered.  
When compared to the pertinent control groups, amylin caused a stronger relative suppression of food 
intake in rats fed the 1% protein diet than in animals receiving the 8% or 18% protein diets (Figure 7). 
This effect was significant at 30 min when comparing the 1% vs. the 8% protein diet group, and after 
60 min vs. both the 8% and the 18% diets. 
 
Figure 5 Average food intake of the three isocaloric diets that differed in protein content over 48 hrs 
before each food intake trial. Data are expressed as means ± SEM. Bars with different letters are 
significantly different (p < 0.05; one way ANOVA) (n = 12 for 1%, 8% and 18%). 
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Saline
Amylin
Figure 6 Effect of amylin (5µg/kg s.c.) on food intake in rats kept on different test diets (1%, 8%, 
18%) for 48 hrs prior to injection. Bars represent group means ± SEM. (n = 12: 1% and 18%; n = 10: 
8 %) *p<0.05, and ***p<0.001 significantly different from respective control (saline) group at 
individual time points (paired Student t test).  
 
Figure 7 Food intake of amylin treated rats relative to their respective saline treated controls 
(=100%). Bars with different letters are significantly different from each other (p < 0.05 one way 
ANOVA; New Man Keuls post hoc test). 
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Effect of an 18% and an 1% protein diet on amylin-induced c-Fos expression in the AP  
 
To investigate the influence of the isocaloric diets on amylin-induced c-Fos expression in the AP, we 
conducted immunohistological c-Fos studies. We found no difference in the number of c-Fos-IR cells 
between rats fed 18% fed and 1% at baseline (2.9 ± 1.8 vs. 4.1 ± 1.4 c-Fos-IR cells/section). However, 
the amylin-induced c-Fos response in the AP of animals that were fed the 18% diet was lower than in 
animals fed the 1% diet (10.6 ± 3.8 vs. 18.1 ± 2.5 c-Fos-IR cells/section). See Figure 8. 
Representative immunostainings of all experimental groups are shown in Figure 9. 
 
Figure 8 Quantification of the number of c-Fos-IR nuclei in the AP of ad libitum fed rats that received 
two different diets (1% or 18% protein) and that were treated with amylin (5µg/kg s.c.) or saline. Data 
are expressed as means ± SEM (n=7). Bars with different letters are significantly different. (one way 
ANOVA). 
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1% protein diet / saline  1% protein diet / amylin 
18% protein diet / saline  18% protein diet / amylin 
Figure 9 Representative immunohistochemical c-Fos stainings of 20µm coronal sections of the AP 
region of rats fed for 48 hrs with the 1% or 18% protein diet and that received amylin (5µg/kg s.c.) or 
saline; rats were injected  at dark onset and perfused two hours later. Left: Under control conditions 
(1% or 18%/Saline), c-Fos IR cells were almost absent in both diet groups. Right: In rats fed the 1% 
diet,  amylin induced a stronger c-Fos response than in rats fed with the 18% protein diet (scale bar 
50µm) 
 
 
 
 
 
. 
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5.2 Effect of peripherally administered amino acids on the anorectic effect 
of amylin and on the amylin induced c-Fos expression in the AP 
 
Course of the blood amino acid and hormone concentration after injection of two different doses of 
amino acids 
 
The effect of Aminoven injection on blood amino acid levels was investigated in 24 hrs fasted rats. 
The lower Aminoven dose (1g/kg) induced a significant rise of amino acid levels in five of the sixteen 
amino acids included in the Aminoven solution after 20 min; for most of the other amino acids, there 
was a trend for an increase after 20 min. All amino acids had nearly returned to baseline by 60 min 
after injections. The higher Aminoven dose (2g/kg) caused a significant rise of amino acid levels after 
20 min in ten out of sixteen amino acids included in the Aminoven solution; most of the amino acids 
did not return to baseline levels after 60 min and remained elevated. Interestingly, lysine levels 
actually decreased after 20 min with both Aminoven doses injected. After 60 min, levels had turned 
back to baseline levels. Overall, the concentration of all amino acids measured showed a (non 
significant) increase at an Aminoven dose of 1g/kg, the increase was significant for the higher dose 
injected. 
Blood glucose dropped significantly after 20 min in the rats that had received the higher Aminoven 
dose (2g/kg: 7.7 ± 0.5 to 5.3 ± 0.3 mM p < 0.05; 1g/kg: 7.7 ± 0.5 to 6.7 ± 0.5 mM; Figure 10).  
There was also a significant increase in amylin and leptin levels after 20 min in the 1g/kg treated 
animals, and in amylin, glucagon, insulin and PP concentrations in the rats injected with 2g/kg 
Aminoven. In the animals injected with the higher dose, glucagon levels were still increased after 60 
min compared to the 20 min value. This was not observed in the rats receiving 1g/kg Aminoven. 
Further leptin was still significantly increased after 60 min in the 2 g/kg Aminoven injected rats. 
(Figure 10). 
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Figure 10 Blood amino acid levels after injection of two different doses of amino acids: the form of 
Aminoven ?= basal value; ? = 1g/kg ? = 2g/kg. Significant differences vs. basal control values: # p 
< 0.05 (1g/kg Aminoven) ; ? p < 0.05 (2g/kg Aminoven); unpaired t-test. 
 
 
 
Figure 11 Blood hormone levels after injection of two different doses of amino acids. ?= basal 
value; ? = 1g/kg amino acids ? = 2g/kg amino acids. Significant differences vs. basal control 
values: # p < 0.05 (1g/kg Aminoven) ; ? p < 0.05 (2g/kg Aminoven); unpaired t-test. 
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Effect of Aminoven on amylin induced c-Fos expression in the AP  
 
Based on the previous experiments, we also tested the influence of an Aminoven injection on the 
amylin-induced c-Fos expression in the AP. Four experimental groups of 24h fasted rats were treated 
with saline / saline, saline / amylin, Aminoven / saline or with Aminoven / amylin. Aminoven was 
given 20 min before amylin which was injected at dark onset.  
The quantitative analysis revealed that the amylin-induced c-Fos response in the AP of the saline / 
amylin treated animals was significantly higher than in the Aminoven / amylin group (43.9 ± 3.5 vs. 
25.4 ± 5.1 c-Fos-IR cells/section). Only little c-Fos was found in the saline / saline and Aminoven / 
saline treated controls. (3.4 ± 2.1 vs. 3.1 ± 1.2 c-Fos-IR cells/section). In the NTS there was no 
difference between the two amylin treated groups, but the c - Fos expression was significantly higher 
compared to saline controls. See Figure 12, Figure 13 and Figure 14 for quantification and for 
representative immunostainings of all experimental groups. 
 
 
Figure 12 Effect of Aminoven pre-treatment on the amylin-induced c-Fos expression in the AP of 24h-
fasted rats. Aminoven (1g/kg i.p.), amylin (5µg/kg s.c.) (aminoven/saline: n = 8; aminoven/amylin: n 
= 7, saline/saline: n = 5 , saline/amylin: n = 7). Data are expressed as means ± SEM. Significant 
differences are indicated by different letters (p< 0.05 one way ANOVA). 
 
Figure 13 Effect of Aminoven pre-treatment on the amylin-induced c-Fos expression in the NTS of 
24h-fasted rats. Aminoven (1g/kg i.p.), amylin (5µg/kg s.c.) (aminoven/saline: n = 8; 
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aminoven/amylin: n = 7, saline/saline: n = 5 , saline/amylin: n = 7). Data are expressed as means ± 
SEM. Significant differences are indicated by different letters (p< 0.05 one way ANOVA).  
 
 
saline / saline  saline / amylin 
 
Aminoven / saline  Aminoven / amylin 
Figure 14 Immunohistochemical c-Fos stainings (20µm coronal sections of the AP region) of rats 
fasted for 24 hrs and treated with Aminoven 1g/kg i.p. or saline and amylin (5µg/kg s.c.) or saline. 
Left: Under control conditions, c-Fos IR cells were almost absent under both conditions. Right: 
amylin (5µg/kg) induced a weaker c-Fos response in animals pre-treated with amino acids (scale bar 
50µm). 
 
Influence of Aminoven injection on amylin’s inhibitory effect on eating  
 
To test the influence of peripherally injected amino acids on amylin's anorectic effect, the animals 
were fed with the 1% protein diet. Amylin reduced food intake when rats were fed with this diet for 24 
hrs. The effect was significant after 30 min and 60 min compared to controls. Surprisingly prior amino 
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acid injection (1g/kg) did not alter amylin’s inhibitory effect on eating. After 120 min no difference in 
cumulative food intake was observed among all four groups (Figure 15) 
 
Figure 15 Effect of amylin (5µg/kg s.c.), injected at dark onset, on food intake in rats kept on the 1% 
protein diet for 24 hrs. Rats were injected with Aminoven (1g/kg i.p.) 20 min before dark onset. Bars 
represent group means ± SEM. (n = 12) * p <0.05, *p <0.01 and ***p <0.001 significantly different 
from respective control (saline) group (paired Student t test within saline or aminoven groups, 
respectively). 
5.3 Effect of glucagon on the amylin induced c-Fos expression in the AP 
 
Influence of glucagon on the c-Fos expression induced by amylin  
 
In this experiment, the animals were distributed into six experimental groups to test if glucagon has an 
acute effect on the amylin induced c-Fos expression in the AP.  
At both doses tested, glucagon alone did not induce a c-Fos response in the AP and NTS. Furthermore, 
there was no significant difference in the number of c-Fos positive cells after amylin among the 
groups irrespective of whether they had been treated with glucagon or not (Figure 16 and Figure 17). 
Representative immunostainings of all experimental groups are shown in Figure 18. 
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Figure 16 Quantification of the number of c-Fos-IR nuclei in the AP in 24 hrs fasted rats that received 
either saline and glucagon (100µg/kg or 500µg/kg i.p) and saline or amylin, respectively 
(saline/saline: n = 6; saline/amylin: n = 8, glucagon 100µg/kg/saline: n = 5 , glucagon 100µg/kg 
/amylin: n = 8, glucagon 500µg/kg/saline: n = 6 , glucagon 500µg/kg/amylin: n = 6). Data are 
expressed as means ± SEM. Bars with different letters are significantly different (one way ANOVA). 
 
Figure 17 Quantification of the number of c-Fos-IR nuclei in the NTS in 24 hrs fasted rats that 
received either saline and glucagon (100µg/kg or 500µg/kg i.p) and saline or amylin, respectively 
(saline/saline: n = 6; saline/amylin: n = 8, glucagon 100µg/kg/saline: n = 5 , glucagon 100µg/kg 
/amylin: n = 8, glucagon 500µg/kg/saline: n = 6 , glucagon 500µg/kg/amylin: n = 6). Data are 
expressed as means ± SEM. Bars with different letters are significantly different (one way ANOVA). 
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saline / saline  saline / amylin 
 
glucagon 100µg/kg / saline  glucagon 100µg/kg / amylin 
glucagon 500 µg/kg / saline  glucagon 500µg/kg / amylin 
Figure 18 Representative immunohistochemical c-Fos stainings of 20µm coronal sections of the AP 
region of rats fasted for 24 hrs and treated with saline or glucagon (100µg/kg or 500µg/kg i.p.) or 
saline and amylin (5µg/kg s.c.), respectively . Left: Under control conditions (saline/glucagon 
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100µg/kg/glucagon 500µg/kg) c-Fos IR cells were almost absent. Right: All three groups treated with 
amylin (5µg/kg) had a similarly strong c-Fos response irrespective to their glucagon treatment (scale 
bar 50µm). 
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The aim of the present study was to extend the findings of Michel (Michel et al., 2007) that diet-
derived protein attenuates the effects of amylin on c-Fos expression in the AP and on food intake. In 
contrast to these previous studies using non-caloric mash that was selectively supplemented with 
nutrients, isocaloric diets with different protein content were used in the present study. This largely 
eliminated the possibility that differences in caloric intake exerted a confounding influence on the 
experimental outcome. The same holds true for possible differences in blood glucose levels, which did 
not differ between animals fed the different protein diets in the current experiments. 
The mechanisms underlying the protein-dependent suppression of amylin responsiveness as 
determined by c-Fos immunocytochemistry and amylin's effect on eating are still unknown. Because a 
given dose of exogenous amylin resulted in similar plasma amylin concentrations irrespective of the 
protein content of the diet, modulation of amylin responsiveness is most likely due to a post - receptor 
effect and not due to a difference in the metabolism (and hence circulating half life of exogenous 
amylin). To test whether a postabsorptive increase in circulating amino acids might be a contributing 
factor, the effect of an intraperitoneal amino acid injection on amylin-induced anorexia and AP 
activation was determined in rats fed the 1 % protein diet. Amino acid injection lead to an acute 
elevation of circulating amino acids, without prior passage and absorption via the gastrointestinal tract.  
It is also an open question whether hormonal stimuli might be indirectly involved in the protein de-
pendent attenuation of amylin responsiveness. At least with respect to the control of glucose 
homeostasis, glucagon is a functional counterplayer to amylin (and insulin). Moreover, blood 
glucagon levels are known to increase in particular in response to protein intake (Geary et al., 1981). 
However, neurophysiological studies characterizing the effect of glucagon in the central nervous 
system are scarce. Therefore we also tested the possible interaction between exogenous glucagon and 
amylin in c-Fos studies.  
6.1 Effect of isocaloric diets with different protein contents on the 
anorectic effect of amylin and on the amylin-induced c-Fos expression 
in the AP/NTS 
The acceptance of the different diets was similar. There was no difference in total food intake of the 
1% protein diet vs. the 18% protein diet. Hence, the lower total blood amino acid concentrations of the 
1% protein diet vs. the 18% protein diet are due to the different protein content of the diets. The lower 
blood amino acid concentration under the 8% protein diet vs. the 18% protein also appears to be a 
consequence of the different protein contents of these diets. It cannot be excluded, however, that 
slightly lower baseline intake of the 8% protein diet might have contributed to the decreased 
concentration of blood amino acids. The reason for the lower intake of the 8% protein diet remains 
unknown at present.  
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Since all diets were isocaloric, it is unlikely that differences in energy intake account for the 
differences in amylin responsiveness under the different feeding conditions. The current studies also 
most likely rule out that diet-dependent differences in blood glucose might have had an influence on 
the effects of amylin. This issue is of particular interest because amylin-sensitive neurons have been 
shown to be glucose-responsive (Adachi et al., 1995; Riediger et al., 2002). Furthermore, amylin’s 
inhibition of gastric emptying which also depends on the AP is overridden by hypoglycemia (Young et 
al., 1999); the latter has been interpreted to be based on the co-sensitivity of AP neurons to amylin and 
glucose. Previous studies suggested that a low glucose concentration of (approximately 3.5 mM) in 
rats fed a lard containing non-caloric mash did not prevent amylin-induced anorexia and c-Fos 
expression in the AP (Michel et al., 2007). Therefore a glucose-dependent attenuation of amylin's 
action on AP neurons does not seem to occur unless hypoglycemia is more pronounced. Hence, such 
effects cannot account for the differences in amylin signaling under our experimental, euglycemic 
conditions, particularly because there were no differences in glucose levels among the diet groups.  
Our studies demonstrate that amylin’s anorectic action is stronger in rats fed a 1% protein diet 
compared to the 8% or 18% protein diets, indicating that diet-derived protein attenuates amylin’s 
suppressive effect on food intake. This result is consistent with and extends previous experiments 
(Michel et al., 2007) investigating the effect of diet-derived nutrients on amylin-responsiveness using 
test diets that contained only one single macronutrient (glucose, lard, protein). According to the 
different protein contents, the diets produced significantly different levels of blood amino acids 
(highest value for 18% diet). Hence, a postabsortive effect of amino acids is a possible factor that 
might be relevant for the modulation of amylin-sensitivity under the different diet conditions that we 
tested here.  
Interestingly, amylin’s anorectic effect was similar in rats receiving the 8% and 18% protein diets. 
Therefore, dynamic effects of the protein content on amylin responsiveness seem to occur at protein 
contents of the diet lower than 8%, at least when an animal is fed ad libitum. Notably, under free 
living conditions, protein supply is likely to vary, both with respect to the frequency of intake (food 
availability) and in terms of the diet's protein content. For these reasons short-term excursions in 
protein supply might modulate amylin-responsiveness under normal feeding conditions. This is 
supported by recent unpublished follow-up studies showing that a 5h period of food deprivation is 
sufficient to increase amylin-induced activation of AP neurons (c-Fos) relative to ad libitum chow-fed 
controls (unpublished results).  
To test whether the attenuation of amylin’s anorectic action is paralleled by a reduced amylin-
mediated AP activation, the effects of amylin on c-Fos expression were compared in rats fed with a 
1% vs. an 18% protein diet. In line with the observations of the behavioral experiments, amylin 
induced a lower c-Fos response in animals receiving the 18% protein diet. The excitatory action of 
amylin on AP neurons is considered the primary neuromechanism underlying amylin’s feeding 
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inhibitory effect. It is therefore conceivable that the impact of diet-derived protein on amylin’s feeding 
effect is mediated by an attenuation of amylin-responsiveness of AP neurons.  
It might appear unexpected that despite a low c-Fos response, amylin produced a significant anorectic 
response in rats receiving the 18% protein diet. However, these results are consistent with our previous 
studies (Michel et al., 2007) conducted with nutritionally equivalent standard chow. Both the amylin- 
induced c-Fos expression and the anorectic response to amylin were similar to the current results. In 
general, the following consideration has to be taken into account. Although c-Fos is an accepted and 
useful marker for neuronal activation, the thresholds for amylin-induced c-Fos expression, amylin-
induced neuronal activation and amylin’s effects on feeding do not necessarily correspond. The 
current studies are not designed to correlate these parameters directly, but they support the concept 
that a protein-dependent decrease in neuronal amylin responsiveness (c-Fos expression) is associated 
with a decreased anorectic effect of exogenous amylin. This has to be clearly segregated from the 
question whether the thresholds for these effects are the same.  
In summary the current studies confirmed that blood amino acid concentrations change depending on 
the protein content of the diet, and that amylin`s anorectic action is stronger in rats fed a 1% protein 
diet compared to 8% or 18% protein diets. Amylin responsiveness of AP neurons is attenuated by diet-
derived protein. This effect does not depend on differences in caloric intake or blood glucose levels. 
6.2 Effect of peripherally administered amino acids on the anorectic effect 
of amylin and on the amylin induced c-Fos expression in the AP 
Based on the assumption that diet derived protein attenuates amylin responsiveness, we investigated if 
peripherally injected amino acids attenuate amylin’s anorectic effect and the amylin induced c-Fos 
response in the AP/NTS.  
Both doses of Aminoven (1g/kg or 2g/kg) produced transient increases in blood amino acid levels, 
although this increase was not always significant for all of the in Aminoven contained amino acids. 
Blood glucose and hormone (e.g. insulin) levels are known to change in response to an increase in 
blood amino acid levels; it was e.g. shown by Liu et al. (2008) that l-arginine, l-lysine, l-alanine, l-
proline, l-leucine and l-glutamine acutely stimulate insulin secretion from mouse islets in a dose-
dependent manner. Under our conditions blood glucose values decreased transiently only in response 
to the higher amino acid dose. Similarly, the higher dose of amino acids resulted in a stronger 
stimulation of pancreatic (e.g. insulin, glucagon) and gastrointestinal hormone release (e.g. PYY). To 
limit the possible impact of these factors, the lower dose of Aminoven was chosen for the subsequent 
c-Fos and feeding experiments.  
Our studies clearly show that a dose of amylin (5µg/kg s.c.) that induces a strong c-Fos response in 24 
h fasted rats (Michel et al., 2007) is attenuated by peripherally injected amino acids (1g/kg). In the 
control group receiving amino acids without amylin, only a low number of c-Fos positive cells was 
present in the AP. This indicates that the amino acid stimulus per se did not affect c-Fos expression. 
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The neuronal activation pattern in the NTS was similar to the effects observed in the AP. This is in 
line with previous demonstrations that the amylin induced c-Fos expression in the NTS is secondary to 
the activation of AP neurons (Riediger et al., 2004).  
The amino acid dependent attenuation of the amylin-induced AP activation did not translate into an 
attenuation of amylin’s hypophagic feeding response in animals fed a 1% protein diet. In other words 
amylin reduced eating in rats fed this diet irrespective of whether they had received a prior Aminoven 
injection or not. Whether the effect of Aminoven on amylin-induced AP activation was not strong 
enough to affect amylin’s feeding response or whether such an effect might have been masked by 
counteracting mechanisms is unclear. Such mechanisms might involve the effect of anorectic 
hormones (e.g. glucagon) stimulated by the amino acid treatment. Although we tried to keep the effect 
of the Aminoven treatment on hormone secretion (e.g. insulin, glucagon, PP, PYY, leptin) small, we 
cannot exclude the possibility that hormonal stimuli interfered with the effect of amino acids (see also 
6.3). It appears unlikely, however that the Aminoven-stimulated amylin secretion that we observed 
might have counteracted a possible attenuation of amylin responsiveness by the amino acid treatment. 
In relation to the increase in plasma amylin levels produced by the amylin injection in rats fed with the 
different protein diets for 24 hrs, the increase in endogenous amylin induced by Aminoven treatment 
appears to be too low. Overall and based on our findings we conclude that an acute increase in blood 
amino acid levels attenuates the amylin induced c-Fos response. Under the current experimental 
condition we could not demonstrate an attenuation of amylin’s anorectic effect by peripherally applied 
amino acids.  
6.3 Effect of glucagon on the amylin induced c-Fos expression in the AP 
To further investigate possible indirect mechanisms involved in the protein-dependent reduction of the 
amylin induced AP activation we tested if the pancreatic hormone glucagon might play a role. Plasma 
glucagon levels increase during protein meals in rats and humans (Geary et al., 1981), and amino acids 
(especially arginine, alanine and glutamine) are potent stimulators of glucagon secretion (Pipeleers et 
al., 1985; Young and Denaro, 1998; Dumonteil et al., 2000). 
Based on the documented anorectic action of glucagon (e.g. Geary and Smith, 1982; Le Sauter et al., 
1991; Geary et al., 1993; Lutz et al., 1996) it might appear counterintuitive to assume that glucagon 
release might be involved in the reduction of amylin responsiveness mediated by diet-derived protein. 
However, despite the accepted anorectic effect of glucagon, some studies demonstrate a glucagon-
mediated increase in food intake under some experimental conditions (Hell and Timo-Iaria, 1985). 
Furthermore, glucagon is a physiological counterplayer to amylin and insulin action, at least with 
respect to the control of glucose homeostasis (Young et al., 1993; Lutz et al., 1998b; Lutz et al., 2001; 
Young, 2005b). 
In our hands, however, acute injections of two different glucagon doses did not attenuate the amylin-
induced c-Fos response in the AP, which at least argues against a short-term interaction between 
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amylin and glucagon with respect to neuronal AP activity. Further, at both doses, glucagon alone did 
not elicit an appreciable c-Fos expression in the AP. It remains to be clarified whether an elevation of 
blood glucagon levels over a longer period of time than under the acute setting might have an impact 
on amylin signalling. 
6.4 Perspectives and significance 
The current studies further support and extend the evidence that diet-derived nutrients, in particular 
protein, attenuate amylin’s AP-mediated suppression of food intake; however, the cellular mechanisms 
still need to be identified. In relation to this question, it is of interest whether the protein-dependent 
attenuation of neuronal AP sensitivity is specific to amylin or whether other hormonal stimuli are also 
affected. Amylin sensitive neurons have been shown to be co-sensitive to the anorectic hormone 
glucagon-like peptide 1 (Riediger, 2000). Hence, it would be interesting to test whether fasting also 
increases the GLP-1 mediated activation (c-Fos) of AP neurons and whether this effect is protein 
dependent. A negative outcome would suggest a specific effect of diet-derived protein on amylin 
responsiveness. A positive outcome might suggest that the protein-mediated attenuation of neuronal 
sensitivity may be specific for amylin-sensitive neurons but not restricted to a single excitatory 
stimulus. In the latter case, it might be interesting to test the effect of fasting on other hormonal stimuli 
that are unrelated to the control of food intake. Such a stimulus could be angiotensin II, which 
modulates baroreceptor function via the AP (McKinley et al., 1992). Preliminary results conducted in 
a follow-up study seem to indicate that the angiotensin II induced c-Fos expression in the AP is not 
enhanced by fasting. Moreover, angiotensin II sensitive neurons do not seem  to express the CTR, 
indicating that these cells are not amylin sensitive because the CTR represents the necessary core 
component of functional amylin receptors. This suggests indirectly that the increase in sensitivity of 
AP neurons induced by fasting and by a decreased protein intake in the diet might be specific for 
amylin responsive cells. 
  
The current findings imply that there is an inverse relation between amylin responsiveness and protein 
intake. Although this effect is unrelated to caloric intake per se it affects the amylin-induced inhibition 
of food intake. One possible physiological implication might be that intake of metabolically more 
important fuels in omnivores (carbohydrates and fats) is less strongly inhibited when their content in 
the diet is low relative to protein. A further possible implication might be that other AP-dependent 
actions of amylin are also modulated by the protein intake. At least the inhibitory effect of amylin on 
gastric emptying is mediated by the AP (Young, 2005b). Based on the current findings one may 
speculate that the amylin-dependent inhibition of gastric emptying is stronger after a period of fasting 
or low protein intake. Such a mechanism might adapt digestive function to a sudden increase in food 
or protein intake. It was beyond the scope of the current studies to investigate these issues. 
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In addition to possible physiological implications, there might be a therapeutic relevance because 
amylin analogs are promising drugs for the treatment of obesity and associated metabolic disorders 
(diabetes mellitus). Based on our current findings the effectiveness of amylin analogs could be 
modulated by the protein intake, which might affect the treatment outcome. 
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7 Abbreviations 
A adrenergic neurons 
AM adrenomedullin  
AP  area postrema 
BBB  blood brain barrier 
BSTL  bed nucleus of the stria terminalis 
CCK  cholecystokinine 
Ce  central nucleus of the amygdala 
CGRP  calcitonin - gene related peptide 
CNS  central nervous system 
CTR  calcitonin receptor 
CVO  circumventricluar organ 
GLP1  glucagon like peptide 1 
lPB  lateral parabrachial nucleus 
NA noradrenergic neurons  
NCM  non caloric mash 
NPY  neuropeptide Y 
NTS  nucleus of the solitary tract 
PB  phosphate buffer 
POMC  proopiomelanocortin 
PP  pancreatic polypeptide 
PYY  peptide tyrosine tyrosine 
RAMP  receptor activity modifying proteins 
SFO  subfornical organ 
SSA  sulfosalicyclic acid solution  
UPLC Ultra Performance Liquid Chromatography  
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